Cargando...
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor pro...
Gardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6515843/ https://ncbi.nlm.nih.gov/pubmed/31156799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719847059 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|